Effect of abiraterone acetate treatment on the quality of life of patients with metastatic castration-resistant prostate cancer after failure of docetaxel chemotherapy.

@article{Harland2013EffectOA,
  title={Effect of abiraterone acetate treatment on the quality of life of patients with metastatic castration-resistant prostate cancer after failure of docetaxel chemotherapy.},
  author={S. J. Harland and John N. Staffurth and Arturo Molina and Yanni Hao and Dennis D. Gagnon and Cora N Sternberg and David Cella and Karim S Fizazi and Christopher J. Logothetis and Thian San Kheoh and Christopher M. Haqq and Johann S de Bono and Howard I. Scher},
  journal={European journal of cancer},
  year={2013},
  volume={49 17},
  pages={3648-57}
}
BACKGROUND In a recent randomised, double-blind, phase III clinical trial among 1195 patients with metastatic castration-resistant prostate cancer (mCRPC) who had failed docetaxel chemotherapy, abiraterone acetate was shown to significantly prolong overall survival compared with prednisone alone. Here we report on the impact of abiraterone therapy on the health-related quality of life (HRQoL) observed during this trial, assessed using the validated Functional Assessment of Cancer Therapy… CONTINUE READING
24 Citations
0 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-10 of 24 extracted citations

Similar Papers

Loading similar papers…